CSI Market
Sign In | Register

Arcutis Biotherapeutics Inc (ARQT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ARQT quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Arcutis Biotherapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-16.14
Depreciation & amortization0.00
Amortization of Other Assets4.67
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-7.33
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation40.36
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest1.76
Operating Lease Right Of Use Asset Amortization Expense-
Issuance Of Temporary Equity License Agreement Noncash Expense-
Acquired In Process Research And Development-
Increase Decrease In Operating Lease Liabilities-0.68
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-73.16
Increase (Decrease) in Accounts Payable-1.69
Increase (Decrease) in Accrued Liabilities50.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.01
Other Working Capital0.00
Other Noncash Income (Expense)0.65
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.09
Discontinued operations0.00
Net Cash flow from Operating Activities-5.63
Investing Activities
Capital Expenditures-10.69
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities227.42
Payments to Acquire Available-for-sale Securities, Debt-246.99
Real Estate Investments0.00
Payment Of Milestone For Intangible-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-30.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.97
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of At The Market Offering-
Proceeds From Issuance Of Shares Under At The Market Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.97
Effect of exchange rate on cash flow0.17
Discontinued operations0.00
Free Cash Flow-16.31
Total Cash Flow-28.74
4 historic quarters locked

Sign in to unlock the full Arcutis Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Arcutis Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: arqt-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001787306-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License